Abstract
The diagnostics of prostate cancer are currently based on three pillars: prostate biomarker panel, imaging techniques, and histological verification. This paper presents a diagnostic algorithm that can serve as a “road map”: from initial patient stratification to the final decision regarding treatment. The algorithm is based on a review of the current literature combined with our own experience. Diagnostic algorithms are a feature of an advanced healthcare system in which all steps are consciously coordinated and optimized to ensure the proper individualization of the treatment process. The prostate cancer diagnostic algorithm was created using the prostate specific antigen and in particular the Prostate Health Index in the first line of patient stratification. It then continued on the diagnostic pathway via imaging techniques, biopsy, or active surveillance, and then on to the treatment decision itself. In conclusion, the prostate cancer diagnostic algorithm presented here is a functional tool for initial patient stratification, comprehensive staging, and aggressiveness assessment. Above all, emphasis is placed on the use of the Prostate Health Index (PHI) in the first stratification of the patients as a predictor of aggressiveness and clinical stage of prostrate cancer (PCa). The inclusion of PHI in the algorithm significantly increases the accuracy and speed of the diagnostic procedure and allows to choose the optimal pathway just from the beginning. The use of advanced diagnostic techniques allows us to move towards to a more advanced level of cancer care. This diagnostics algorithm has become a standard of care in our hospital. The algorithm is continuously validated and modified based on our results.
Highlights
Prostate cancer (PCa) is the most frequent malignant disease to occur in men
Considering the side effects of radical prostatectomy, which is indicated in the case of highly aggressive PCa (GS ≥ 7), active surveillance seems to be the suitable option for PCa with low aggressiveness (GS < 7)
A significant advantage of [68 Ga]-prostate-specific membrane antigen (PSMA)-11 is that lesions characteristic of lymph node metastases are frequently presented in very high contrast when compared to choline
Summary
Prostate cancer (PCa) is the most frequent malignant disease to occur in men. According to The International Agency for Research on Cancer (IARC), 1,414,259 new cases of PCa were reported and 375,304 men died of PCa worldwide in 2020 [1]. Differences in the incidence rate of PCa worldwide primarily reflect differences in the use of. PCa is a based highly heterogeneous disease,prostate ranging from a clinically insignificant and manifestation that requires only active to a highly aggressive panel, imaging techniques, histological verification. Thissurveillance, paper presents a diagnostic castration-resistant type of tumor that requires a quick and radical course of action. Difalgorithm that can serve as a “road map” delineating the course of treatment: from initial ferences in the incidence rate of PCa worldwide primarily reflect differences in the use of patient stratification to the final decision regarding treatment. The diagnostics of PCa are currently based on three pillars: prostate biomarker panel, imaging. This paper presents a diagnostic algorithm that can serve as a “road map” delineating the course of treatment: from initial
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
